MyFinsight
Home
Blog
About
Accounts receivable
-$9,031K
(-122.92%↓ Y/Y)
Stock-based compensation
expense
$3,226K
(-33.66%↓ Y/Y)
Non-cash interest
expense
$2,807K
(-77.43%↓ Y/Y)
Accounts payable
$2,602K
(74.51%↑ Y/Y)
Write-down of inventory
$1,727K
(1401.74%↑ Y/Y)
Deferred revenue
$1,673K
(-69.76%↓ Y/Y)
Non-cash operating lease
expense
-$1,224K
(45.14%↑ Y/Y)
Depreciation
$585K
(-7.14%↓ Y/Y)
Impairment of fixed assets
$64K
Other long-term
assets
-$39K
(62.14%↑ Y/Y)
Net cash provided by
(used in) operating...
$3,525K
(-59.75%↓ Y/Y)
Canceled cashflow
$19,453K
Increase (decrease) in
cash, cash...
-$7,092K
(-108.30%↓ Y/Y)
Canceled cashflow
$3,525K
Proceeds from issuance of
common stock, net of...
$3,240K
(-95.12%↓ Y/Y)
Proceeds from the
exercise of stock options
$85K
(-87.12%↓ Y/Y)
Net income (loss)
-$8,908K
(-240.08%↓ Y/Y)
Accrued expense and
other current...
-$5,441K
(-128.98%↓ Y/Y)
Prepaid expenses and
other current assets
$2,172K
(161.74%↑ Y/Y)
Operating lease
liabilities
-$1,189K
(55.08%↑ Y/Y)
Inventory
$655K
(-94.80%↓ Y/Y)
Change in fair value of
warrant liability
-$566K
(-108.29%↓ Y/Y)
Non-cash royalty revenue
related to sale of future...
$402K
(-53.42%↓ Y/Y)
Other long-term
liabilities
-$119K
(-119.67%↓ Y/Y)
Bad debt expense
-$1K
(-100.10%↓ Y/Y)
Net cash provided by
(used in) financing...
-$6,538K
(-108.53%↓ Y/Y)
Net cash provided by
(used in) investing...
-$4,079K
(-14667.86%↓ Y/Y)
Canceled cashflow
$3,325K
Repayment of wcf liability
$8,362K
Purchase of ipr&d asset
$3,000K
Purchases of equipment
$1,079K
(649.31%↑ Y/Y)
Repayment of liability
related to settlement...
$1,501K
Back
Back
Cash Flow
Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. (AKBA)
source: myfinsight.com